There are currently 295 active clinical trials seeking participants for Prostate Cancer research studies. The states with the highest number of trials for Prostate Cancer participants are California, New York, Texas and Ohio.
Experiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer Patients
NCT06500741
Recruiting
The purpose of this study is to quantify the preferences for novel hormonal therapy (NHT) +/- androgen-deprivation therapy (ADT) vs ADT monotherapy among patients with non-metastatic hormone-sensitive prostate cancer (PC) in the United States (US), Germany, Spain, France, Italy, the United Kingdom (UK), South Korea, Australia, and Brazil, using a discrete choice experiment (DCE).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: Analysis Group, Inc., Boston, Massachusetts
Conditions: Prostate Cancer
Register for Updates
SpaceIT Hydrogel System for Perirectal Spacing
NCT06451614
Recruiting
To evaluate the safety and effectiveness of the SpaceIT™ Hydrogel System in patients undergoing External Beam Radiotherapy (EBRT) for the treatment of prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/13/2025
Locations: Baptist Hospital of Miami, Miami, Florida +8 locations
Conditions: Prostate Cancer
Register for Updates
Castrate Resistant Prostate Cancer Enhertu Therapy
NCT06610825
Recruiting
Use of Enhertu as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Washington DC VAMC, Washington DC, District of Columbia
Conditions: Prostate Cancer Metastatic, Prostate Cancer, CRPC
Register for Updates
African Cancer Genome: GMD
NCT05754658
Recruiting
The goal of this study is to develop a comprehensive characterization of genetic and molecular drivers of breast and prostate cancer in individuals of African ancestry. The study is conducted by the African Caribbean Cancer Consortium (AC3) and involves the recruitment of patients from nine international AC3 research sites in the Bahamas, Barbados, Benin, Burkina Faso, Haiti, Jamaica, Kenya, Namibia, and Trinidad and Tobago, and the US. The main questions are to: molecularly characterize genomic... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/11/2025
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Breast Cancer, Prostate Cancer
Register for Updates
Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer
NCT05477823
Recruiting
The purpose of this study is to evaluate the imaging and gene expression biomarkers in prostate cancer. Participants have high-risk prostate cancer and have indicated they will undergo external beam radiation therapy, brachytherapy, and androgen deprivation therapy (EBRT+BTX+ADT). Participants can expect to be in this study for up to 5 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Prostate Cancer
Register for Updates
HIFU for Focal Ablation of Prostate Tissue: an Observational Study
NCT03620786
Recruiting
The Sonablate HIFU device was approved by the U.S.FDA for prostate tissue ablation in October, 2015. The purpose of this observational research study is to investigate the localized treatment of prostate cancer using HIFU through clinical data and health-related quality of life (HRQOL) questionnaires.
Gender:
MALE
Ages:
Between 40 years and 85 years
Trial Updated:
03/11/2025
Locations: University of California, Los Angeles, Los Angeles, California
Conditions: Prostate Cancer
Register for Updates
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer
NCT05169970
Recruiting
The researchers are doing this study to find out if stereotactic body radiation therapy (SBRT) without androgen deprivation therapy (ADT) is an effective treatment approach for people with unfavorable intermediate-risk prostate. The researchers will see whether SBRT can prevent participants' cancer from coming back and/or spreading to other parts of the body. In addition, they will look closely at how safe and effective it is to rely on Decipher test results for determining which patients would... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Prostate Cancer
Register for Updates
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT04644068
Recruiting
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
03/10/2025
Locations: Research Site, San Francisco, California +79 locations
Conditions: Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5, Non-small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer, Gastric Cancer, Biliary Cancer, Cervical Cancer, Endometrial Cancer, Small Cell Lung Cancer Only in Module 5
Register for Updates
A Pilot Study Evaluating the Effect of 2D Antiscatter Grids on CBCT Image Quality
NCT04565457
Recruiting
This is Pilot study that investigates the CBCT(Cone beam computed tomography) image quality improvement provided by the 2D antiscatter grid technology. The primary objective is to assess the improvement in tissue visualization in an observer study, which will be conducted in a blinded fashion.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/10/2025
Locations: University of Colorado Hospital, Aurora, Colorado +1 locations
Conditions: Prostate Cancer, Head and Neck Cancers, Upper Abdomen Cancers
Register for Updates
A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
NCT05530655
Recruiting
This study will establish the preferred dose of lisinopril in men with non-metastatic prostate cancer undergoing radiation treatment. This study will also evaluate the effect of lisinopril on urinary symptoms and the impact of lisinopril on biomarkers and their association with urinary symptoms.
Gender:
MALE
Ages:
Between 18 years and 70 years
Trial Updated:
03/07/2025
Locations: Wilmot Cancer Institute, Rochester, New York
Conditions: Prostate Cancer, Radiation Toxicity, Urinary Complication
Register for Updates
Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr
NCT05948657
Recruiting
This study will be assessing the ability of PSMA-PET CT to determine the absence of clinically significant prostate cancer in patients on active surveillance (AS) with low risk and favorable intermediate-risk prostate cancer.
Gender:
MALE
Ages:
Between 18 years and 90 years
Trial Updated:
03/06/2025
Locations: UCLA, Los Angeles, California +3 locations
Conditions: Prostate Cancer
Register for Updates
Contributions to Hypertension With Androgen Deprivation Therapy
NCT05700903
Recruiting
This study plans to learn more about contributors to high blood pressure in men who undergo androgen deprivation therapy (ADT) to treat prostate cancer. Prostate cancer is the most common non-skin cancer in men, affecting approximately 1 in 8 American men and its primary treatment is through the use of ADT. However, ADT increases the likelihood of developing heart disease including high blood pressure. This study will determine if dysfunction of the nervous system and/or kidneys occurs in men un... Read More
Gender:
MALE
Ages:
40 years and above
Trial Updated:
03/06/2025
Locations: UCHealth University of Colorado Hospital, Aurora, Colorado
Conditions: Androgen Deprivation Therapy, Prostate Cancer, Hypertension, Autonomic Dysfunction, Renal Disease
Register for Updates